This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, X. X. Articles by Ikegaki, N. Search for Related Content PubMed PubMed Citation Articles by Tang, X. X. Articles by Ikegaki, N.

The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma

¹ AFLAC Cancer Center, Department of Pediatrics and Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia; ² The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; ³ Department of Pediatrics, Northwestern University and Children's Memorial Hospital, Chicago, Illinois; ⁴ Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁵ The Children's Hospital of Los Angeles, Los Angeles, California

Requests for reprints: Naohiko Ikegaki, Emory Children's Center, Room 444, 2015 Uppergate Drive Northeast, Atlanta, GA 30322. Phone: 404-778-5726; Fax: 404-727-4455; E-mail: nao_ikegaki{at}oz.ped.emory.edu.

MYCN amplification strongly predicts adverse outcome of neuroblastoma. However, the significance of MYCN expression in the clinical and biological behavior of neuroblastoma has been unclear. To address this question, we first examined the expression of MYCN in combination with TrkA (a favorable prognostic indicator of neuroblastoma) in 91 primary neuroblastoma by quantitative reverse transcription-PCR and investigated the relationship among patient survival, MYCN, and TrkA expressions. Three subsets of neuroblastoma were defined based on MYCN and TrkA expression. Neuroblastoma expressing the highest level of MYCN but little TrkA were MYCN-amplified cases, which had a 5-year survival of 9.3%. Interestingly, MYCN and TrkA expression showed a linear correlation (r = 0.5664, P < 0.00005) in neuroblastoma lacking MYCN amplification, and the 5-year survival of neuroblastoma patients with low MYCN and low TrkA expressions was 63.7%, whereas those with high expression of both had a 5-year survival of 88.1% (P < 0.00005). This nonlinear distribution of disease outcome relative to MYCN expression in neuroblastoma explains why MYCN expression is not predictive of neuroblastoma disease outcome by dichotomous division of the neuroblastoma cohort. However, high-level MYCN expression is associated with favorable outcome in neuroblastoma lacking MYCN amplification. Furthermore, forced expression of MYCN significantly suppresses growth of neuroblastoma cells lacking MYCN amplification by inducing apoptosis and enhancing favorable neuroblastoma gene expression. Collectively, these data suggest that high-level MYCN expression in neuroblastoma lacking MYCN amplification results in a benign phenotype. Thus, the high MYCN expression confers the opposite biological consequence in neuroblastoma, depending on whether or not MYCN is amplified. (Cancer Res 2006; 66(5): 2826-33)

This article has been cited by other articles:

				E. Fredlund, M. Ringner, J. M. Maris, and S. Pahlman High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma PNAS, September 16, 2008; 105(37): 14094 - 14099. [Abstract] [Full Text] [PDF]

				C. Stock, E. Bozsaky, F. Watzinger, U. Poetschger, L. Orel, T. Lion, A. Kowalska, and P. F. Ambros Genes Proximal and Distal to MYCN Are Highly Expressed in Human Neuroblastoma as Visualized by Comparative Expressed Sequence Hybridization Am. J. Pathol., January 1, 2008; 172(1): 203 - 214. [Abstract] [Full Text] [PDF]

				N. Ikegaki, T. Gotoh, B. Kung, J. S. Riceberg, D. Y. Kim, H. Zhao, E. F. Rappaport, S. L. Hicks, R. C. Seeger, and X. X. Tang De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene Clin. Cancer Res., October 15, 2007; 13(20): 6001 - 6009. [Abstract] [Full Text] [PDF]

				F. Westermann, K.-O. Henrich, J. S. Wei, W. Lutz, M. Fischer, R. Konig, R. Wiedemeyer, V. Ehemann, B. Brors, K. Ernestus, et al. High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status Clin. Cancer Res., August 15, 2007; 13(16): 4695 - 4703. [Abstract] [Full Text] [PDF]

				A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465. [Abstract] [Full Text] [PDF]

				D. T. Martin, R. L. Gendron, J. A. Jarzembowski, A. Perry, M. H. Collins, C. Pushpanathan, E. Miskiewicz, V. P. Castle, and H. Paradis Tubedown Expression Correlates with the Differentiation Status and Aggressiveness of Neuroblastic Tumors Clin. Cancer Res., March 1, 2007; 13(5): 1480 - 1487. [Abstract] [Full Text] [PDF]

				J. Fang, Q. J. Quinones, T. L. Holman, M. J. Morowitz, Q. Wang, H. Zhao, F. Sivo, J. M. Maris, and M. L. Wahl The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma Mol. Pharmacol., December 1, 2006; 70(6): 2108 - 2115. [Abstract] [Full Text] [PDF]